A new study in mice found that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission. This approach shows such promise that it's already being tested in an ongoing clinical trial in people with advanced bladder cancer.
U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials.
Nektar and Syndax, which have new data on immuno-oncology drugs due for presentation at ASCO in the coming days, have agreed to pair them up in a combination trial.
Let’s add one more big loser to the lengthy roster of wins and defeats during the ASCO preview round.
Genentech has agreed to lend its closely-watched checkpoint inhibitor atezolizumab to Syndax for a combo study with the Waltham, MA-based biotech's lead drug entinostat for triple-negative breast cancer, just three days after Syndax landed an $80 million crossover round.
Merck adds another immuno-oncology tie-up
Roche open to alliances in hunt for cancer drug combinations
Merck ties up with tiny Syndax on a `breakthrough` cancer combo